Publications

Olexiy Sagan, Ruslan Yakubsevitch, Krassimir Yanev, Roman Fomkin, Emily Stone, Daniel Hines, John O’Donnell, Alita Miller, Robin Isaacs, Subasree Srinivasan

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam With Imipenem/Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

AAC Accepted Manuscript posted online December 16, 2019

John O’Donnell, Richard A. Preston, Grigor Mamikonyan, Emily Stone, Robin Isaacs

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

American Society for Microbiology, Antimicrob. Agents Chemother. August 2019 63:e00794-19; Accepted manuscript posted online 15 July 2019, doi:10.1128/AAC.00794-19 OPEN ACCESS

Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor, Zoliflodacin

Journal of Clinical Microbiology

Melissa D. Barnes, Vijay Kumar, Christopher R. Bethel, Samir H. Moussa, John O’Donnell, Joseph D. Rutter, Caryn E. Good, Kristine M. Hujer, Andrea M. Hujer, Steve H. Marshall, Barry N. Kreiswirth, Sandra S. Richter, Philip N. Rather,k,l Michael R. Jacobs, Krisztina M. Papp-Wallace, Focco van den Akker, Robert A. Bonomo

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone B-Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone B-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

mBio. 2019 10(2): e00159-19

Adam B. Shapiro, Janelle Comita-Prevoir, and Mark Sylvester

5-Carboxytetramethylrhodamine-Ampicillin Fluorescence Anisotropy-Based Assay of Escherichia coli Penicillin-Binding Protein 2 Transpeptidase Inhibition

ACS Infectious Diseases

Iyer R, Moussa S, Tommasi R, Miller A.

Role of the Klebsiella pneumoniae TolC porin in antibiotic efflux

National Center for Biotechnology Information

Stephanie N. Taylor, M.D., Jeanne Marrazzo, M.D., M.P.H., Byron E. Batteiger, M.D., Edward W. Hook, III, M.D., Arlene C. Seña, M.D., M.P.H., Jill Long, M.D., M.P.H., Michael R. Wierzbicki, Ph.D., Hannah Kwak, M.H.S., Shacondra M. Johnson, B.S.P.H., Kenneth Lawrence, Pharm.D., and John Mueller, Ph.D.

Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

New England Journal of Medicine

John O' Donnell, Ken Lawrence, Karthick Vishwanathan, Vinayak Hosagrahara, John P. Mueller

Single-dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

AAC Accepted Manuscript posted online October 29, 2018

Anthony D. Cristillo, PhD, MS; Claire C. Bristow, PhD, MPH, MSc; Elizabeth Torrone, MSPH, PhD; Jo-Anne Dillon, MSc, PhD, FCAHS, FRSC; Robert D. Kirkcaldy, MD, MPH , Huan Dong, MS; Yonatan H. Grad, MD, PhD; Robert A. Nicholas, PhD; Peter A. Rice, MD; Kenneth Lawrence, PharmD; David Oldach, MD, FIDSA; William Maurice Shafer, PhD; Pei Zhou, PhD; Teodora E. Wi, MD; Sheldon R. Morris, MD, MPH; and Jeffrey D. Klausner, MD, MPH

Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting

Journal of Sexually Transmitted Diseases

Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP, Stone E

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

AAC Accepted Manuscript Posted Online 20 August 2018